[et_pb_section fb_built=”1″ admin_label=”Listings” module_id=”target group” _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” background_enable_image=”off” background_size=”custom” background_image_width=”90%” background_position=”bottom_right” custom_padding=”||0px|||” top_divider_height=”51px” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row use_custom_gutter=”on” gutter_width=”3″ _builder_version=”4.27.5″ _module_preset=”default” width=”100%” custom_margin=”||30px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.5″ _module_preset=”b327cbe4-b1d5-4b66-ad37-40c8f2f061ba” header_text_color=”#10344C” header_font_size=”50px” header_2_font=”||||||||” header_2_text_align=”left” header_2_text_color=”#10344C” header_2_font_size=”45px” header_2_line_height=”1.35em” custom_margin=”||15px||false|false” header_2_font_size_tablet=”32px” header_2_font_size_phone=”20px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” custom_margin=”||||false|false” hover_enabled=”0″ text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
ClinicalTrials.gov ID:<\/strong> NCT05507203 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464, Administered Once Daily, for Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis.<\/p>\n This is a multicenter, randomized, placebo-controlled study to investigate the efficacy and safety of ABX464 at a dosage of 25 mg or 50 mg once daily for the induction of clinical remission in patients with moderately to severely active ulcerative colitis.<\/p>\n Patients who have had an inadequate response, no response, loss of response, or intolerance to conventional therapies \u2013 including corticosteroids and immunosuppressants (e.g., azathioprine, 6-mercaptopurine, methotrexate) \u2013 will be included.<\/p>\n In addition, patients may also be included who have had an inadequate response, loss of effect, or intolerance to advanced therapies, including:<\/p>\n The aim of the study is to assess whether ABX464 is effective and safe at the stated dosages in achieving clinical remission in this patient group.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" ABTECT-1 Study on Ulcerative Colitis ABTECT-1 \u2013 Evaluation of Treatment with ABX464 for Ulcerative Colitis \u2013 1 ClinicalTrials.gov ID: NCT05507203Sponsor: Abivax S.A. (Information provided by Abivax S.A. (responsible party)) Official Title A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464, Administered Once Daily, for Induction Therapy in Patients […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[36],"tags":[],"class_list":["post-485","post","type-post","status-publish","format-standard","hentry","category-for-study-partners"],"yoast_head":"\n
Sponsor:<\/strong> Abivax S.A. (Information provided by Abivax S.A. (responsible party))<\/p>\nOfficial Title<\/h3>\n
Study overview<\/h3>\n
\n